Analyst Joseph Stringer from Needham maintained a Buy rating on Alnylam Pharma and increased the price target to $520.00 from $478.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Buy rating due to a combination of factors including Alnylam Pharma’s impressive financial performance and promising outlook. The company reported a significant increase in total product revenue for the third quarter of 2025, surpassing both the firm’s and market expectations. This growth was largely driven by the success of Amvuttra in treating ATTR-CM, which has led to an upward revision of the company’s revenue guidance for the year.
Despite some concerns over a subpoena from the U.S. Attorney’s Office, which may pose a short-term risk, the overall outlook for Alnylam’s TTR franchise remains positive. The strong revenue growth and the potential for continued success in their product launches have led to an increase in the price target, reinforcing the Buy rating. Stringer remains optimistic about the company’s future prospects, despite the current challenges.